APOGEPHA Arzneimittel GmbH   Report issue

For profit Phase 3
Founded: Dresden Germany (1882)
Status: Left NME R&D (2019)

Organization Overview

First Clinical Trial
2004
NCT00603343
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2010

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (2)

propiverine (4 trials)

tolterodine (detrol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Disease (Phase 3)

Enuresis (Phase 3)

Urinary Bladder Diseases (Phase 3)

Urinary Bladder, Neurogenic (Phase 3)

Urinary Bladder, Overactive (Phase 3)

Urinary Incontinence (Phase 3)

Urologic Diseases (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 2